Related Experiment Video
Updated: Apr 10, 2026
09:34
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
2.4K
Exploring the potential of adjunct therapy in tuberculosis
Geetha Vani Rayasam1, Tanjore S Balganesh2
1CSIR-Open Source Drug Discovery (OSDD) Unit, Council for Scientific and Industrial Research, Anusandhan Bhavan, 2 Rafi Marg, New Delhi, India.
Trends in Pharmacological Sciences
|June 16, 2015
Summary
Novel therapies are crucial for drug-resistant tuberculosis (TB). Host-directed adjunct therapies offer a promising strategy to shorten treatment duration and combat resistant Mycobacterium tuberculosis (Mtb) strains.
Area of Science:
- Microbiology
- Immunology
- Pharmacology
Background:
- Drug-resistant tuberculosis (TB) presents a critical unmet need for novel, safe, and shorter treatment regimens.
- Current TB drug discovery often targets essential Mycobacterium tuberculosis (Mtb) genes, necessitating new strategies like host-directed therapies.
- Adjunct therapies targeting host pathways or nonmicrobicidal proteins offer a paradigm shift, potentially reducing treatment duration and overcoming resistance.
Purpose of the Study:
- To discuss novel strategies for treating drug-resistant tuberculosis (TB).
- To explore the potential of host-directed and nonmicrobicidal adjunct therapies.
- To highlight recent advances and challenges in developing new TB treatments.
Main Methods:
- Review of recent advances in targeting host-pathogen interactions.
- Identification of host pathways implicated in TB, such as eicosanoid regulation and angiogenesis.
- Exploration of drug repurposing for TB treatment, including metformin and verapamil.
Main Results:
- Host-directed adjunct therapies show potential for shorter TB treatment durations due to novel mechanisms and reduced resistance.
- Pathways like eicosanoid regulation and angiogenesis are implicated in host-pathogen interactions relevant to TB.
- Existing drugs like metformin and verapamil are identified as candidates for TB treatment repurposing.
Conclusions:
- Host-directed and pathogen-directed adjunct therapies are essential for a paradigm shift in TB treatment.
- Targeting host pathways and nonmicrobicidal proteins offers a viable strategy to overcome drug resistance and shorten treatment.
- Further research into these adjunct therapies and drug repurposing holds significant promise for combating TB.
Related Concept Videos
01:28Pulmonary Tuberculosis V
911
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
911
01:26Pulmonary Tuberculosis IV
741
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
741
01:29Pulmonary Tuberculosis I
1.5K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
01:28Pulmonary Tuberculosis II
2.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.3K
01:31Pulmonary Tuberculosis III
1.5K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.5K
01:22Heart Failure VI: Adjunct Therapies
599
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
599